Search
Search your stock
Analysis
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY)
Ranking:
Sell
Implies negative momentum
Stock Name: Alnylam Pharmaceuticals, Inc.
Symbol: ALNY
Market Cap: $36.09B
Industry: Biotechnology
Sector: Healthcare
Website: https://www.alnylam.com
About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1) Please visit their website for more information.

Overview:
Last Close: $279.82
52 Week: $143.31-$300.55
MVA50: 273.62
MVA200: 230.50
RSI: 48.58
Buy/Sell*: 36.46
1-Month change: 1.34%
3-Month change: 8.83%
*Proprietary Buy Sell Volume Indicator
Price Chart For ALNY
Financial Parameters Most Recent Quarter: (2024-Q3),2024-09-30
Revenue: $420M
Revenue Growth (YOY): -44.02%
Profit (% of Rev): 99.07%
Income (% of Rev): -26.56%
Income Growth (YOY): -175.51%
Operating Income: $-77M
Operating Cash Flow: $44M
Operating Cash Flow Growth (YoY): -87.84%
Annual Dividend Yield: 0.00%
Total Assets: $4.21B
Total Liabilities: $4.17B
Cash & Equivalent: $1.10B
Total Debt: $1.30B
Debt/Equity: 40.24
Quick Ratio: 2.69
Current Ratio: 2.75
Price/Book: 1093.10
Price/Earnings: -79.25
EBITDA: $-77M
EPS: -0.87
Our Approach

Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.

TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.

Contact @ support@theoryofstocks.com

© 2024 Stock Articles. All rights reserved.

This site uses cookies to ensure the best experience. By continuing to use this site, you agree to their use.

Click here for Cookie Policy